Discontinuation of asthma drug leaves patients in search of alternative; FDA’s approach to artificial intelligence (AI) raises opportunities and challenges; landmark FDA approval signals hope for millions with severe food allergies.
Patients are caught in the crossfires of a dispute between a drug company and pharmacy benefit managers (PBMs), with no end in sight, according to The Hill. GSK discontinued making fluticasone propionate (Flovent)—the most common asthma inhaler for children—at the start of this year and instead is offering an authorized generic, which many PBMs won't cover. As pharmaceutical companies and PBMs clash over the pricing and distribution of these asthma medications, patients find themselves facing uncertainty and potential disruptions in their treatment plans.
As artificial intelligence (AI) continues to revolutionize health care, the FDA's shifting stance on regulating AI-driven medical technologies becomes increasingly pivotal, according to Politico. Amidst the promise of improved diagnostics and treatments, concerns over safety, efficacy, and equitable access underscore the need for a balanced regulatory framework. Furthermore, stakeholders across the health care ecosystem must navigate these complexities to harness AI's full potential while ensuring patient safety and equitable health care outcomes. The FDA plans to ask Congress for new authority to regulate these technologies.
The FDA's recent approval of omalizumab (Xolair) for treating food allergies represents a significant advancement in addressing severe allergic reactions, according to NPR. With omalizumab previously approved for asthma and chronic hives, this expansion offers hope to millions of individuals who grapple with potentially life-threatening food allergies. As health care professionals prepare to integrate omalizumab into treatment protocols, patients and advocates anticipate a newfound sense of security and improved quality of life for those at risk of severe allergic reactions.
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More